Eli Lilly Raised Its Outlook. Is the Stock a Buy Now? [Yahoo! Finance]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Yahoo! Finance
Despite nearly doubling over the past 12 months, Eli Lilly stock still has heaps of upside according to investment bank analysts who follow the century-old pharmaceutical giant. Barclay's , an investment bank, recently raised its price target on the pharma giant to $913 per share. At recent prices, a $913 per-share target suggests Lilly stock could climb about 17% over the next 12 months. Let's look at the reasons why Wall Street's still bullish for this high-flying stock to see if it's a smart buy now for everyday investors. Eli Lilly's sales keep defying gravity Experienced investors rarely see established pharmaceutical companies raise revenue by double-digit annual percentages. Thanks to soaring sales of multiple new treatments, big gains are the new normal for Eli Lilly. First-quarter sales of tirzepatide, a drug marketed as Zepbound for weight management and Mounjaro for diabetes, soared to $2.3 billion from just $568 million in the previous-year period. Tirzepatide isn
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Eli Lilly's (LLY) Efsitora Matches Daily Insulins in A1C Control [Yahoo! Finance]Yahoo! Finance
- Meet the GLP-1 Drug That Could Be the Biggest Concern for Eli Lilly and Novo Nordisk [Yahoo! Finance]Yahoo! Finance
- Stanley Druckenmiller makes surprising small-cap and AI stock bet [Yahoo! Finance]Yahoo! Finance
- Investors put $400M into biotech licensing obesity drugs from China [Yahoo! Finance]Yahoo! Finance
- Viking falls after Roche's obesity drug data [Seeking Alpha]Seeking Alpha
LLY
Earnings
- 4/30/24 - Beat
LLY
Sec Filings
- 5/9/24 - Form 8-K
- 5/3/24 - Form SD
- 4/30/24 - Form 10-Q
- LLY's page on the SEC website